STICHTING HARTWIG MEDICAL FOUNDATION

Their core work

Hartwig Medical Foundation is a Dutch non-profit that generates, curates, and shares whole-genome sequencing (WGS) data from cancer patients at clinical scale — one of the largest such repositories in Europe. Their core contribution is turning raw tumor genomic data into research-grade, standardized datasets that meet FAIR principles and can be federated across borders without moving raw data. In H2020 projects they functioned as a specialist data provider and standards contributor, bringing real clinical genomic assets rather than purely methodological expertise. Their work sits at the intersection of oncology, bioinformatics, and health data governance.

What they specialise in

How they've shifted over time

Their H2020 entry point was cancer-specific: EUCANCan focused tightly on genomics, cancer, standardization, and cross-border data sharing for oncology research. As they moved into B1MG, the scope broadened significantly toward population-level personalised medicine, European genomic infrastructure (EOSC, 1+MG), and formal data quality frameworks including FAIR principles and ELSI considerations. The shift signals a maturation from a cancer data specialist toward a broader role in European genomic data governance and infrastructure — less disease-specific, more foundational platform thinking.

Hartwig is moving from being a cancer-data asset holder toward a European genomic infrastructure contributor, making them increasingly relevant to any consortium building cross-border health data platforms or seeking compliance with the 1+MG and EHDS frameworks.

How they like to work

Hartwig participates exclusively as a consortium partner — they have not led any H2020 project, which is consistent with a foundation whose value is its data asset rather than project management capacity. Despite never coordinating, they engage in large, multi-national consortia: 54 unique partners across 19 countries across just two projects, indicating they are sought-after contributors rather than passive members. Working with them likely means accessing their genomic database and standardization expertise rather than expecting them to drive project administration.

With 54 consortium partners across 19 countries from only 2 projects, Hartwig operates in large, geographically diverse European networks — typical of the 1+MG and EUCANCan ecosystems which span virtually all EU member states. Their network is broad rather than deep, suggesting they bring a widely recognized data asset that attracts diverse partners rather than maintaining recurring bilateral relationships.

What sets them apart

Hartwig Medical Foundation holds one of Europe's most clinically comprehensive whole-genome sequencing databases for cancer patients, which very few academic or research organizations can match in scale or data quality. This makes them a uniquely valuable node in any federated health data consortium: they do not just study genomics — they generate and govern real patient-derived genomic data at production scale. For consortium builders targeting personalised medicine or cancer genomics, Hartwig provides the data infrastructure credential that strengthens both the scientific case and the regulatory trust argument.

Highlights from their portfolio

• EUCANCan
  The largest of their two projects (EUR 530,650 EC funding, 2019–2023), this federated cancer genomics network positioned Hartwig as a core infrastructure node for homogeneous cross-border WGS data analysis.
• B1MG
  Though minimally funded (EUR 2,704 EC contribution), B1MG — the Beyond 1 Million Genomes coordination action — carries outsized strategic significance as the policy and infrastructure backbone for the EU's 1+MG initiative, signaling Hartwig's seat at the European genomic governance table.